Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

381. Public information about osteoporosis: what's available, what's needed

Public information about osteoporosis: what's available, what's needed Public information about osteoporosis: what's available, what's needed Public information about osteoporosis: what's available, what's needed Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Office of Technology Assessment. Public information about osteoporosis: what's available, what's needed. Washington DC: U. S. Congress. Office of Technology Assessment (OTA) 1994: 62 Authors' objectives To develop policy options for public information on osteoporosis. Authors' conclusions Although there is a large quantity of public information about osteoporosis, the information is not well disseminated; it is not tailored to the different needs of particular

1994 Health Technology Assessment (HTA) Database.

382. [Osteoporosis therapy in the Basque Country]

[Osteoporosis therapy in the Basque Country] Actuacion ante la osteoporosis en el Pais Vasco [Osteoporosis therapy in the Basque Country] Actuacion ante la osteoporosis en el Pais Vasco [Osteoporosis therapy in the Basque Country] Rico R, Asua J, Gutierrez M, Baile M Citation Rico R, Asua J, Gutierrez M, Baile M. Actuacion ante la osteoporosis en el Pais Vasco. [Osteoporosis therapy in the Basque Country] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-94-03. 1994 (...) Authors' objectives

To consider the status of osteoporosis in the Basque Country and the extent of the consequences resulting from its treatment, to propose the treatment guidelines and to evaluate the suitability of the bone density measurements as a matter of routine.

Authors' conclusions Conclusions and recommendations: Recommendations have been put forward regarding measures for the prevention of senile osteoporosis and post-menopausal osteoporosis as well as for the rationalization

1994 Health Technology Assessment (HTA) Database.

383. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. (Abstract)

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. Prolonged corticosteroid therapy increases the risk of osteoporosis and fracture. We studied whether corticosteroid-induced osteoporosis could be prevented by treatment with calcium, calcitriol (1,25-dihydroxyvitamin D3), and calcitonin.One hundred three patients starting long-term corticosteroid therapy were randomly assigned to receive 1000 mg of calcium per day orally and either calcitriol (0.5

1993 NEJM Controlled trial quality: uncertain

384. Recruitment methods for screening programmes: trial of an improved method within a regional osteoporosis study

Recruitment methods for screening programmes: trial of an improved method within a regional osteoporosis study Recruitment methods for screening programmes: trial of an improved method within a regional osteoporosis study Recruitment methods for screening programmes: trial of an improved method within a regional osteoporosis study Torgerson D J, Garton M J, Donaldson C, Russell I T, Reid D M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Recruitment for screening for osteoporosis Type of intervention Screening Economic study type Cost-effectiveness analysis Study population Women aged 45-49 years Setting Osteoporosis screening unit (primary care). The economic study was carried out in Aberdeen, U. K. Dates to which

1993 NHS Economic Evaluation Database.

385. Treatment of postmenopausal osteoporosis with calcitriol or calcium. (Abstract)

Treatment of postmenopausal osteoporosis with calcitriol or calcium. Osteoporosis is a common problem whose management is controversial. To evaluate the efficacy and safety of calcitriol (1,25-dihydroxyvitamin D3) in the treatment of postmenopausal osteoporosis, we conducted a three-year prospective, multicenter, single-blind study in 622 women who had one or more vertebral compression fractures. The women were randomly assigned to receive treatment with calcitriol (0.25 micrograms twice a day (...) ). There was no significant difference between the groups in the incidence of side effects requiring withdrawal of treatment (8.6 percent in the calcitriol group vs. 6.5 percent in the calcium group).Continuous treatment of postmenopausal osteoporosis with calcitriol for three years is safe and significantly reduces the rate of new vertebral fractures in women with this disorder.

1992 NEJM Controlled trial quality: uncertain

386. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Full Text available with Trip Pro

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. To study the dose related response of salmon calcitonin (salcatonin) given intranasally on bone mass and bone turnover and the effect of salcatonin on rates of fracture in elderly women with moderate osteoporosis.Double blind, placebo controlled, randomised group comparison.Outpatient clinic for research into osteoporosis.208 healthy women aged 68-72 years who had a bone (...) with salcatonin to about one third of that in the non-salcatonin treated women (relative risk 0.23 (0.07 to 0.77)).The results suggest that, compared with calcium alone, salcatonin given intranasally reduces the rates of fracture by two thirds in elderly women with moderate osteoporosis. Furthermore, it increases spinal bone mass in a dose dependent manner.

1992 BMJ Controlled trial quality: predicted high

387. Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study. Full Text available with Trip Pro

Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study. To estimate the response rates and operating costs of three recruitment methods within a regional osteoporosis screening programme.Randomised trial of three types of invitation letter: one offering fixed appointments with option to change time, one offering fixed appointments but requiring telephoned confirmation of intention to attend, and one inviting recipient to telephone to make

1992 BMJ Controlled trial quality: uncertain

388. Screening for osteoporosis to prevent fractures

Screening for osteoporosis to prevent fractures Screening for osteoporosis to prevent fractures Screening for osteoporosis to prevent fractures NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Screening for osteoporosis to prevent fractures. University (...) Replacement Therapy; Hip Fractures; Mass Screening; Menopause; Osteoporosis Language Published English Country of organisation England Address for correspondence University of York, York, Y01 5DD, United Kingdom. Tel: +44 1904 321040, Fax: +44 1904 321041, Email: crd@york.ac.uk AccessionNumber 31995000029 Date bibliographic record published 23/08/1996 Date abstract record published 23/08/1996 Health Technology Assessment (HTA) database Copyright © 2019 University of York Homepage Options Print PubMed

1992 Health Technology Assessment (HTA) Database.

389. Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study

Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study Garton M J, Torgerson D J, Donaldson C, Russell I T, Ried D M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Recruitment for screening for osteoporosis Type of intervention Screening Economic study type Cost-effectiveness analysis Study population Women aged 45-49 years Setting Osteoporosis screening unit (primary care). The economic study was carried out in Aberdeen, U. K. Dates to which data relate Effectiveness

1992 NHS Economic Evaluation Database.

390. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. (Abstract)

Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. Osteoporosis among older women is a major public health problem. We studied the effects of three approaches to the prevention of osteoporosis in women with low bone density.One hundred twenty postmenopausal women (mean [+/- SD] age, 56 +/- 4) who were selected because they had low forearm bone density were enrolled in a double-blind, placebo-controlled

1991 NEJM Controlled trial quality: uncertain

391. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. (Abstract)

Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. Although fluoride increases bone mass, the newly formed bone may have reduced strength. To assess the effect of fluoride treatment on the fracture rate in osteoporosis, we conducted a four-year prospective clinical trial in 202 postmenopausal women with osteoporosis and vertebral fractures who were randomly assigned to receive sodium fluoride (75 mg per day) or placebo. All received a calcium supplement (...) gastrointestinal symptoms and lower-extremity pain. We conclude that fluoride therapy increases cancellous but decreases cortical bone mineral density and increases skeletal fragility. Thus, under the conditions of this study, the fluoride-calcium regimen was not effective treatment for postmenopausal osteoporosis.

1990 NEJM Controlled trial quality: uncertain

392. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. (Abstract)

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. Progressive bone loss in osteoporosis results from bone resorption in excess of bone formation. We conducted a double-blind study in 66 women with postmenopausal osteoporosis of therapy with etidronate, a diphosphonate compound that reduces bone resorption by inhibiting osteoclastic activity. The patients were randomly assigned in equal numbers to receive oral etidronate (...) , biochemical, or bone histomorphometric effects of treatment were observed. We conclude that at the end of nearly three years, etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content and, after approximately one year of treatment, a significant decrease in the rate of new vertebral fractures.

1990 NEJM Controlled trial quality: predicted high

393. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. (Abstract)

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. To determine the effects of etidronate (a bisphosphonate that inhibits osteoclast-mediated bone resorption) in the treatment of postmenopausal osteoporosis, we conducted a prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia.The patients were randomly assigned to treatment with phosphate (1.0 g (...) with postmenopausal osteoporosis.

1990 NEJM Controlled trial quality: predicted high

394. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy

Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy Tosteson A N, Rosenthal D I, Melton J, Weinstein M C Record Status This is a critical abstract of an economic (...) that the protective effect in old age ofHRT may not be nearly as great as suggested here. Bibliographic details Tosteson A N, Rosenthal D I, Melton J, Weinstein M C. Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Annals of Internal Medicine 1990; 113(8): 594-603 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Aged, 80 and over; Bone Density; Cost-Benefit Analysis; Densitometry /economics; Estrogen Replacement

1990 NHS Economic Evaluation Database.

395. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). (Abstract)

Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). In a prospective, randomised, placebo-controlled trial comparing the effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) (150 mg/day) plus calcium (1 g/day) with that of calcium alone on the bone mass of patients receiving long-term glucocorticoid therapy, the mean metacarpal cortical area in patients receiving APD increased by 1.2% between 0 and 6 months (p less than 0.06

1988 Lancet Controlled trial quality: uncertain

396. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. (Abstract)

Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. The risk-benefit ratio of combined fluoride-calcium therapy in primary vertebral osteoporosis was examined prospectively in patients with at least one vertebral fracture. 257 patients were randomised to receive sodium fluoride 25 mg twice daily plus elemental calcium 1 g daily and a vitamin D2 supplement, and 209 received one of the alternative therapies usually prescribed in France. After a follow-up of 24

1988 Lancet Controlled trial quality: uncertain

397. Prevention of spinal osteoporosis in oophorectomised women. (Abstract)

Prevention of spinal osteoporosis in oophorectomised women. 100 women who had taken part in a prospective controlled trial of oestrogen therapy for prevention of post-oophorectomy bone loss were reviewed after a median follow-up period of nine years. A significant reduction in height occurred among the placebo-treated group, but not in the group treated with mestranol (mean 23 x 3 micrograms/day). The placebo-treated group had a higher spine score, lower central vertebral height, and larger

1980 Lancet